Log In
Print
BCIQ
Print
Print this Print this
 

Orencia, abatacept (ONO-4164IV)

Also known as: CTLA4-Ig (formerly BMS-188667IV)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionCTLA-4 (CD152)-Ig fusion protein
Molecular Target CD80 (B7-1) ; CD86 (B7-2)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today